^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Myelodysplastic Syndrome
    Drug:sabatolimab (MBG453) (TIM-3 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Novartis Press Release
    Title:

    Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes

    Published date:
    05/25/2021
    Excerpt:
    Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents.